Skip Navigation

Annals of Oncology 2006 17(3):484-487; doi:10.1093/annonc/mdj143
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Grünberger, B.
Right arrow Articles by Raderer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grünberger, B.
Right arrow Articles by Raderer, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa

B. Grünberger1, W. Hauff2, J. Lukas2, S. Wöhrer1, C. C. Zielinski1, B. Streubel3, A. Chott3 and M. Raderer1,*

Departments of 1 Medicine I, Division of Oncology, 2 Opththalmology, and 3 Pathology Medical University Vienna, Vienna, Austria

* Correspondence to: Prof. M. Raderer, MD, Department of Medicine I, Division of Oncology, Medical University Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria. Tel/Fax: +43-1-40400-2296; E-mail: markus.raderer{at}meduniwien.ac.at

Background: Recent results have implicated Chlamydia, especially Chlamydia psittaci, in the development of ocular adnexal lymphoma in the large majority of patients. We present our experience with ex-juvantibus antibiotic treatment in patients diagnosed with MALT lymphoma of the ocular adnexa.

Patients and methods: A retrospective analysis identified a total of 11 patients (six female, five male) with MALT-lymphoma of the ocular adnexa who were given doxycyclin 200 mg p.o. daily over 3 weeks. Patients were tested also for autoimmune conditions, Helicobacter status and hepatitis along with assessment of MALT-lymphoma specific genetic changes.

Results: After a median follow-up of 9 months, none of the patients responded to ‘blind’ antibiotic treatment with doxycyclin. Only one patient with bilateral conjunctival lymphoma related a short lasting subjective improvement, but was referred to alternative therapy due to progression and worsening symptoms after 6 months.

Conclusions: In this uncontrolled series, no effect of ‘blind’ antibiotic treatment with doxycyclin could be found in our patients with MALT lymphoma of the ocular adnexa. These results are in contrast to other series and suggest a potential geographic difference in the role of Chlamydia in ocular adnexal lymphoma. Thus, antibiotic therapy without prior testing for Chlamydia should be discouraged.

Key words: antibiotic therapy, chlamydia, MALT lymphoma, ocular adnexa


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
A. Stefanovic and I. S. Lossos
Extranodal marginal zone lymphoma of the ocular adnexa
Blood, July 16, 2009; 114(3): 501 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al.
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Ann. Onc., May 1, 2008; 19(5): 835 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
V. M L Cohen, J. Sweetenham, and A. D Singh
Ocular adnexal lymphoma. What is the evidence for an infectious aetiology?
Br J Ophthalmol, April 1, 2008; 92(4): 446 - 448.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al.
Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 242 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ferreri, M Ponzoni, G. Dognini, M-Q Du, C Doglioni, J Radford, R Dolcetti, and F Cavalli
Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial
Ann. Onc., November 1, 2006; 17(11): 1721 - 1722.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. J. M. Ferreri, M. Ponzoni, M. Guidoboni, A. G. Resti, L. S. Politi, S. Cortelazzo, J. Demeter, F. Zallio, A. Palmas, G. Muti, et al.
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.
J Natl Cancer Inst, October 4, 2006; 98(19): 1375 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic
Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options
Blood, September 1, 2006; 108(5): 1451 - 1460.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.